Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance

被引:41
|
作者
Zheng, Ningbo [1 ]
Fang, Jing [1 ]
Xue, Gang [1 ]
Wang, Ziyu [1 ]
Li, Xiaoyin [2 ]
Zhou, Mengshi [2 ]
Jin, Guangxu [1 ]
Rahman, Masmudur M. [3 ]
McFadden, Grant [3 ]
Lu, Yong [1 ]
机构
[1] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27101 USA
[2] St Cloud State Univ, Dept Math & Stat, St Cloud, MN 56301 USA
[3] Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virothera, Tempe, AZ 85287 USA
关键词
ONCOLYTIC VIRUS; DEATH; AUTOPHAGY; MODELS; THERAPY; PROTEIN; AKT;
D O I
10.1016/j.ccell.2022.08.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytotoxicity of tumor-specific T cells requires tumor cell-to-T cell contact-dependent induction of classic tumor cell apoptosis and pyroptosis. However, this may not trigger sufficient primary responses of solid tumors to adoptive cell therapy or prevent tumor antigen escape-mediated acquired resistance. Here we test myxoma virus (MYXV)-infected tumor-specific T (T-MYXV) cells expressing chimeric antigen receptor (CAR) or T cell receptor (TCR), which systemically deliver MYXV into solid tumors to overcome primary resistance. In addition to T cell-induced apoptosis and pyroptosis, tumor eradication by CAR/TCR-T-MYXV cells is also attributed to tumor cell autosis induction, a special type of cell death. Mechanistically, T cell-derived interferon gamma (IFN gamma)-protein kinase B (AKT) signaling synergizes with MYXV-induced M-T5-SKP-1-VPS34 signaling to trigger robust tumor cell autosis. CAR/TCR-T-MYXV-elicited autosis functions as a type of potent bystander killing to restrain antigen escape. We uncover an unexpected synergy between T cells and MYXV to bolster solid tumor cell autosis that reinforces tumor clearance.
引用
收藏
页码:973 / +
页数:20
相关论文
共 50 条
  • [1] INDUCTION OF TUMOR CELL AUTOSIS BY MYXOMA VIRUS-INFECTED CAR-T AND TCR-T CELLS TO OVERCOME PRIMARY AND ACQUIRED RESISTANCE IN SOLID TUMORS
    Lu, Yong
    Zheng, Ningbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A273 - A273
  • [2] Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
    Hiltensperger, Michael
    Krackhardt, Angela M.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells
    Patel, Ashna
    Kutuzov, Mikhail A.
    Dustin, Michael L.
    van der Merwe, P. Anton
    Dushek, Omer
    IMMUNOTHERAPY ADVANCES, 2024, 4 (01):
  • [4] Potent, CRISPR-engineered off-the-shelf CAR-T and TCR-T cells evading host T and NK cell rejection
    Zhang, Y.
    Prodeus, A.
    Yetley, U.
    Tan, Y.
    Ranade, U.
    Balwani, I.
    Liu, D.
    Miller, I.
    Zhang, B.
    Dutta, I.
    Sharma, P.
    Goel, S.
    Malik, V.
    Venkatesan, P.
    Keenan, M.
    Lam, M.
    Arredouani, S.
    Schultes, B. C.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A128 - A128
  • [5] CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
    Rodriguez-Garcia, Alba
    Palazon, Asis
    Noguera-Ortega, Estela
    Powell, Daniel J., Jr.
    Guedan, Sonia
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [6] INVITRO PRIMARY INDUCTION OF CYTOTOXIC T CELLS AGAINST VIRUS-INFECTED SYNGENEIC CELLS
    BLANDEN, RV
    KEES, U
    DUNLOP, MBC
    JOURNAL OF IMMUNOLOGICAL METHODS, 1977, 16 (01) : 73 - 89
  • [7] PCR ASSAY TO IDENTIFY WOODCHUCK HEPATITIS VIRUS POSTTRANSCRIPTIONAL REGULATORY ELEMENT IN CAR-T AND TCR-T CELLS FOR FRESH AND FORMALIN-FIXED SAMPLES
    Pullarkat, Shalini
    Wright, Jocelyn
    Woolston, David
    Kimble, Erik
    Lee, Bo
    Hirayama, Alexandre
    Chapuis, Aude
    Buenrostro, Denise
    Black, Graeme
    Bleakley, Marie
    Seaton, Brandon
    Specht, Jennifer
    Turtle, Cameron
    Yeung, Cecilia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A102 - A102
  • [8] Enhancing CAR-T Cell Metabolism to Overcome Hypoxia in Brain Tumor Microenvironment
    Hatae, Ryusuke
    Kyewalabye, Keith
    Yamamichi, Akane
    Chen, Tiffany
    Phyu, Su
    Chuntova, Pavlina
    Nejo, Takahide
    Okada, Hideho
    CANCER SCIENCE, 2025, 116 : 100 - 100
  • [9] Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective
    Mody, Hardik
    Ogasawara, Ken
    Zhu, Xu
    Miles, Dale
    Shastri, Prathap Nagaraja
    Gokemeijer, Jochem
    Liao, Michael Z.
    Kasichayanula, Sreeneeranj
    Yang, Tong-Yuan
    Chemuturi, Nagendra
    Gupta, Swati
    Jawa, Vibha
    Upreti, Vijay V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (03) : 530 - 557
  • [10] T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells
    Ikeda, Hiroaki
    INTERNATIONAL IMMUNOLOGY, 2016, 28 (07) : 349 - 353